Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Rises By 6.6%

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 7,930,000 shares, a growth of 6.6% from the November 30th total of 7,440,000 shares. Approximately 9.1% of the company’s shares are short sold. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is currently 5.9 days.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after buying an additional 18,997 shares in the last quarter. Franklin Resources Inc. acquired a new position in GoodRx during the third quarter valued at approximately $5,675,000. Sanctuary Advisors LLC bought a new position in GoodRx in the third quarter valued at approximately $85,000. Barclays PLC increased its position in shares of GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares during the last quarter. Finally, Fortem Financial Group LLC bought a new stake in shares of GoodRx during the 3rd quarter worth approximately $772,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Up 3.1 %

GDRX stock traded up $0.14 during trading hours on Wednesday, reaching $4.65. 1,136,538 shares of the stock were exchanged, compared to its average volume of 1,417,009. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -155.00, a PEG ratio of 3.54 and a beta of 1.29. The firm’s 50-day moving average is $5.01 and its 200-day moving average is $6.75. GoodRx has a 12 month low of $4.09 and a 12 month high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Mizuho began coverage on shares of GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Barclays reduced their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Citigroup dropped their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.37.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.